These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

308 related articles for article (PubMed ID: 9379142)

  • 1. Dendritic cells as adjuvants for immune-mediated resistance to tumors.
    Schuler G; Steinman RM
    J Exp Med; 1997 Oct; 186(8):1183-7. PubMed ID: 9379142
    [No Abstract]   [Full Text] [Related]  

  • 2. Why are dendritic cells central to cancer immunotherapy?
    Colaco CA
    Mol Med Today; 1999 Jan; 5(1):14-7. PubMed ID: 10088127
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel perspectives on dendritic cell-based immunotherapy of cancer.
    Bonaccorsi I; Pezzino G; Morandi B; Ferlazzo G
    Immunol Lett; 2013; 155(1-2):6-10. PubMed ID: 24076312
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dendritic cell activation kinetics and cancer immunotherapy.
    Bellone M; Camporeale A; Boni A
    J Immunol; 2004 Mar; 172(5):2727-8. PubMed ID: 14978067
    [No Abstract]   [Full Text] [Related]  

  • 5. Dendritic cells and immunotherapy for malignant disease.
    Reid DC
    Br J Haematol; 2001 Mar; 112(4):874-87. PubMed ID: 11298582
    [No Abstract]   [Full Text] [Related]  

  • 6. Turbocharging vaccines: emerging adjuvants for dendritic cell based therapeutic cancer vaccines.
    Saxena M; Bhardwaj N
    Curr Opin Immunol; 2017 Aug; 47():35-43. PubMed ID: 28732279
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chemokines as adjuvants for immunotherapy: implications for immune activation with CCL3.
    Schaller TH; Batich KA; Suryadevara CM; Desai R; Sampson JH
    Expert Rev Clin Immunol; 2017 Nov; 13(11):1049-1060. PubMed ID: 28965431
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunogenic cell death and cross-priming are reaching the clinical immunotherapy arena.
    Melero I; Arina A; Murillo O; Dubrot J; Alfaro C; Pérez-Gracia JL; Bendandi M; Hervás-Stubbs S
    Clin Cancer Res; 2006 Apr; 12(8):2385-9. PubMed ID: 16638842
    [No Abstract]   [Full Text] [Related]  

  • 9. Use of an immunoisolation device for cell transplantation and tumor immunotherapy.
    Geller RL; Loudovaris T; Neuenfeldt S; Johnson RC; Brauker JH
    Ann N Y Acad Sci; 1997 Dec; 831():438-51. PubMed ID: 9616733
    [No Abstract]   [Full Text] [Related]  

  • 10. Dendritic cells in cancer immunotherapy. 10 January 2005, London, UK.
    George AJ
    IDrugs; 2005 Feb; 8(2):104-6. PubMed ID: 15696407
    [No Abstract]   [Full Text] [Related]  

  • 11. Cryoimmunologic antitumor effects enhanced by dendritic cells in osteosarcoma.
    Kawano M; Nishida H; Nakamoto Y; Tsumura H; Tsuchiya H
    Clin Orthop Relat Res; 2010 May; 468(5):1373-83. PubMed ID: 20232181
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Significance of dendritic cells for the immunotherapy of tumors].
    Weise JB; Maune S; Kabelitz D; Heiser A
    HNO; 2005 Feb; 53(2):117-20. PubMed ID: 15657753
    [No Abstract]   [Full Text] [Related]  

  • 13. Dendritic cell-based immunotherapy: a basic review and recent advances.
    Constantino J; Gomes C; Falcão A; Neves BM; Cruz MT
    Immunol Res; 2017 Aug; 65(4):798-810. PubMed ID: 28660480
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Science, medicine, and the future: Cellular immunotherapy for cancer.
    Armstrong AC; Eaton D; Ewing JC
    BMJ; 2001 Dec; 323(7324):1289-93. PubMed ID: 11731394
    [No Abstract]   [Full Text] [Related]  

  • 15. Adoptive cellular therapy of malignancy.
    Chang AE; Geiger JD; Sondak VK; Shu S
    Arch Surg; 1993 Nov; 128(11):1281-90. PubMed ID: 8239992
    [TBL] [Abstract][Full Text] [Related]  

  • 16. IFN{gamma} markedly cooperates with intratumoral dendritic cell vaccine in dog tumor models.
    Mito K; Sugiura K; Ueda K; Hori T; Akazawa T; Yamate J; Nakagawa H; Hatoya S; Inaba M; Inoue N; Ikehara S; Inaba T
    Cancer Res; 2010 Sep; 70(18):7093-101. PubMed ID: 20823157
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dendritic cell-based combined immunotherapy with autologous tumor-pulsed dendritic cell vaccine and activated T cells for cancer patients: rationale, current progress, and perspectives.
    Morisaki T; Matsumoto K; Onishi H; Kuroki H; Baba E; Tasaki A; Kubo M; Nakamura M; Inaba S; Yamaguchi K; Tanaka M; Katano M
    Hum Cell; 2003 Dec; 16(4):175-82. PubMed ID: 15147037
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biological properties of dendritic cells: implications to their use in the treatment of cancer.
    van Schooten WC; Strang G; Palathumpat V
    Mol Med Today; 1997 Jun; 3(6):254-60. PubMed ID: 9211416
    [TBL] [Abstract][Full Text] [Related]  

  • 19. IFN-alpha in the generation of dendritic cells for cancer immunotherapy.
    Santini SM; Lapenta C; Santodonato L; D'Agostino G; Belardelli F; Ferrantini M
    Handb Exp Pharmacol; 2009; (188):295-317. PubMed ID: 19031032
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Current status and future applications of cellular therapies for cancer.
    Copier J; Bodman-Smith M; Dalgleish A
    Immunotherapy; 2011 Apr; 3(4):507-16. PubMed ID: 21463192
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.